Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration

Trocho, Carme; Escolà‐Gil, Joan Carles; Ribas, Vicent; Benı́tez, Sònia; Martín‐Campos, Jesús M.; Rotllan, Noemí; Osaba, Lourdes; Ordóñez-Llanos, Jordi; González‐Sastre, Francesc; Blanco‐Vaca, Francisco

doi:10.1016/j.atherosclerosis.2004.02.009

Cited by 8 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidemiologic evidence suggests a cardiovascular benefit to this drug [88], and experimental animal study also suggests a reduction in atherosclerosis. In a murine model, phenytoin reduced aortic atherosclerosis [89]. However, the side effects of this medication -including psychomotor retardation, gingival hyperplasia, osteomalacia and coarse facies Fig.…”

Section: Combination Therapymentioning

confidence: 99%

The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases

Choi¹,

Vilahur²,

Yadegar³

et al. 2006

CMM

View full text Add to dashboard Cite

Despite significant progress in the management of atherosclerosis and its resultant complications, cardiovascular disease remains the principal cause of death in the world. The National Cholesterol Education Project Adult Treatment Panel III (NCEP ATP III) recognizes low levels of high-density lipoprotein cholesterol (HDL) as a risk factor for coronary heart disease (CHD) and high levels of HDL as a risk-reducing factor; however, the elevation of HDL as a specific therapeutic target for the prevention and treatment of CHD has yet to be accepted on the same level as low-density lipoprotein (LDL)-reducing therapies. Current HDL elevators including nicotinic acid, fibric acid derivatives, peroxisome proliferator activated receptor (PPAR) agonists and statins also affect other lipid constituents which make interpretation of the clinical trials of these drugs difficult in teasing out the independent effect of HDL elevation. Ample laboratory investigation suggests that HDL elevation would reduce atherosclerotic burden through multiple independent mechanisms. In this review, we explore HDL biology, its potential mechanisms in the treatment of atherosclerotic disease, and promising new drugs with HDL-raising activity.

show abstract

Section: Combination Therapymentioning

confidence: 99%

The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases

Choi¹,

Vilahur²,

Yadegar³

et al. 2006

CMM

View full text Add to dashboard Cite

show abstract

“…An experimental study examining the results of PHT treatment on atherosclerosis susceptibility and lipid profile in mice found that PHT treatment had a protective effect, and that the atherosclerosis prevention was not concomitant with a consistent increase in HDL or any other protective change in the lipid profile. 5 To date, atherosclerosis remains a complex multifactorial disorder that is thought to result from an interaction between the genetic make-up of an individual and various environmental factors. Cytochrome P450 is partly responsible for the biosynthesis of endogenous vasoregulators.…”

Section: Introductionmentioning

confidence: 99%